<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0182376</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-11613</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>HIV diagnosis and management</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>HIV epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Bioinformatics</subject><subj-group><subject>Sequence analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>HIV prevention</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Antiviral therapy</subject><subj-group><subject>Antiretroviral therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Antiviral therapy</subject><subj-group><subject>Antiretroviral therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Public and occupational health</subject><subj-group><subject>Preventive medicine</subject><subj-group><subject>Vaccination and immunization</subject><subj-group><subject>Antiviral therapy</subject><subj-group><subject>Antiretroviral therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Demography</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Characteristics of HIV-infected U.S. Army soldiers linked in molecular transmission clusters, 2001-2012</article-title>
<alt-title alt-title-type="running-head">Soldiers and HIV transmission clusters</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7314-4545</contrib-id>
<name name-style="western">
<surname>Hakre</surname>
<given-names>Shilpa</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jagodzinski</surname>
<given-names>Linda L.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Liu</surname>
<given-names>Ying</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Pham</surname>
<given-names>Peter T.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kijak</surname>
<given-names>Gustavo H.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tovanabutra</surname>
<given-names>Sodsai</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>McCutchan</surname>
<given-names>Francine E.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Scoville</surname>
<given-names>Stephanie L.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cersovsky</surname>
<given-names>Steven B.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Michael</surname>
<given-names>Nelson L.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Scott</surname>
<given-names>Paul T.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Peel</surname>
<given-names>Sheila A.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>U.S. Army Public Health Center, Aberdeen Proving Ground, Maryland, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Switzer</surname>
<given-names>William M.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Centers for Disease Control and Prevention, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>All authors, except Dr. Francine McCutchan, have no competing interests to declare. Dr. McCutchan was hired as a consultant through the Henry M. Jackson Foundation for the Advancement of Military Medicine to work on a project that includes the findings reported in this article. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">shakre@hivresearch.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>7</issue>
<elocation-id>e0182376</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">
<license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">Creative Commons CC0</ext-link> public domain dedication.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0182376"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>Recent surveillance data suggests the United States (U.S.) Army HIV epidemic is concentrated among men who have sex with men. To identify potential targets for HIV prevention strategies, the relationship between demographic and clinical factors and membership within transmission clusters based on baseline <italic>pol</italic> sequences of HIV-infected Soldiers from 2001 through 2012 were analyzed.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>We conducted a retrospective analysis of baseline partial <italic>pol</italic> sequences, demographic and clinical characteristics available for all Soldiers in active service and newly-diagnosed with HIV-1 infection from January 1, 2001 through December 31, 2012. HIV-1 subtype designations and transmission clusters were identified from phylogenetic analysis of sequences. Univariate and multivariate logistic regression models were used to evaluate and adjust for the association between characteristics and cluster membership.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Among 518 of 995 HIV-infected Soldiers with available partial <italic>pol</italic> sequences, 29% were members of a transmission cluster. Assignment to a southern U.S. region at diagnosis and year of diagnosis were independently associated with cluster membership after adjustment for other significant characteristics (p&lt;0.10) of age, race, year of diagnosis, region of duty assignment, sexually transmitted infections, last negative HIV test, antiretroviral therapy, and transmitted drug resistance. Subtyping of the <italic>pol</italic> fragment indicated HIV-1 subtype B infection predominated (94%) among HIV-infected Soldiers.</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>These findings identify areas to explore as HIV prevention targets in the U.S. Army. An increased frequency of current force testing may be justified, especially among Soldiers assigned to duty in installations with high local HIV prevalence such as southern U.S. states.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This work was supported by the U.S. Army Medical Research and Materiel Command under Contract No W81XWH-16-C-0225 and by a cooperative agreement (W81XWH-11-2-0174) between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and the U.S. Department of Defense (DoD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="2"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Due to the sensitive nature and higher likelihood of identification of patients, which could realistically include adverse impact to HIV-infected United States Army personnel still in service and possible insurability and employability impacts, data cannot be made publicly available. For questions about data, contact the Walter Reed Army Institute of Research Public Affairs Office at <email xlink:type="simple">usarmy.detrick.medcom-wrair.mbx.public-affairs@mail.mil</email>.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>The United States (U.S.) national HIV/AIDS strategy (NHAS) was initiated in 2010 for a coordinated national response to the HIV epidemic in the U.S. The 2015 update focused on increased HIV testing, access to, and engagement in, medical care, viral suppression, and access to HIV pre-exposure prophylaxis.[<xref ref-type="bibr" rid="pone.0182376.ref001">1</xref>] The Centers for Disease Control and Prevention (CDC) developed the National HIV Surveillance System (NHSS) to monitor and characterize the U.S. HIV epidemic.[<xref ref-type="bibr" rid="pone.0182376.ref002">2</xref>] Findings from analysis of the molecular component of NHSS surveillance data identified priority areas aligned with the NHAS goal for HIV prevention programs to reduce new infections. Evaluation of NHSS 2001–2012 HIV-1 <italic>pol</italic> sequence data revealed that of 32% who had genetically similar HIV, significantly more HIV-infected men (35%) were in transmission clusters than women (19%). Among men who reported having sex with men (MSM), 92% were linked to other MSM (including MSM who were injecting drug users); MSM, especially older black MSM, were commonly linked to heterosexual women.[<xref ref-type="bibr" rid="pone.0182376.ref003">3</xref>]</p>
<p>New U.S. Army surveillance data suggest the HIV epidemic is concentrated among MSM.[<xref ref-type="bibr" rid="pone.0182376.ref004">4</xref>] A recent investigation, which included sequence and interview data, among HIV-infected Soldiers located at a single Army installation established that a majority of HIV transmission networks within an eighteen-month time period were among MSM.[<xref ref-type="bibr" rid="pone.0182376.ref005">5</xref>] We sought to evaluate factors associated with membership within a transmission cluster Army-wide and over a longer time period in an effort to identify characteristics of Soldiers who would benefit most from HIV prevention services.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec007">
<title>Study population</title>
<p>The study population consisted of all Soldiers in active service and newly-diagnosed with HIV-1 infection from January 1, 2001 through December 31, 2012. A single available baseline partial <italic>pol</italic> sequence, generated for routine HIV medical care for each HIV-infected Soldier, was analyzed for evidence of transmission clusters.</p>
</sec>
<sec id="sec008">
<title>Ethical considerations</title>
<p>The U.S. Army Public Health Center’s Public Health Review Board (#146–12) and the Walter Reed Army Institute of Research Institutional Review Board (#1861-C) determined HIV surveillance program activities were public health practice.</p>
</sec>
<sec id="sec009">
<title>HIV diagnosis</title>
<p>HIV infection has been identified among Soldiers with standard U.S. diagnostic algorithms in use since 1989. Enzyme-linked immunoassay (EIA) initial screen-reactive specimens were tested in duplicate with the same EIA assay. Repeat reactive samples were reflexed to a confirmatory HIV-1 Western Blot assay (Genetic Systems HIV-1 Western Blot, Bio-Rad Laboratories, Redmond, Washington, U.S.). Enhancements to the Army algorithm in 2009 included replacement of a second generation EIA assay with a third generation EIA assay as well as incorporation of a qualitative HIV-1 ribonucleic acid assay to detect acute and/or primary HIV infection; the enhanced algorithm reduced the diagnostic window to 14–18 days post-infection.[<xref ref-type="bibr" rid="pone.0182376.ref006">6</xref>]</p>
</sec>
<sec id="sec010">
<title>Demographic and clinical data</title>
<p>The Army HIV surveillance program, enhanced in 2012,[<xref ref-type="bibr" rid="pone.0182376.ref005">5</xref>] utilizes prospectively collected risk behavior data, existing longitudinal data from medical surveillance (Defense Medical Surveillance System, Armed Forces Health Surveillance Branch) and laboratory databases, and data generated in the course of routine clinical care such as sequence data from antiretroviral resistance testing, baseline CD4 counts, HIV viral load, and co-infection with the sexually transmitted infections (STIs) hepatitis B (HBV) and C virus (HCV), syphilis, <italic>Neisseria gonorrhoeae</italic> (NG), and <italic>Chlamydia trachomatis</italic> (CT).[<xref ref-type="bibr" rid="pone.0182376.ref007">7</xref>]</p>
</sec>
<sec id="sec011">
<title>Sequence data</title>
<p>A 918 base pair partial <italic>pol</italic> sequence available for any Soldier diagnosed with HIV-1 infection from 2001 through 2012 was compiled and aligned using Geneious Pro 5.6.7.[<xref ref-type="bibr" rid="pone.0182376.ref008">8</xref>] Sequence alignment was further refined manually. HIV-1 subtype designations and transmission clusters, defined as ≥2 linked sequences, were identified from phylogenetic analysis of sequences using the maximum likelihood (ML) method and Kimura-2-parameter (K2P) model in MEGA6 (<xref ref-type="supplementary-material" rid="pone.0182376.s001">S1 Fig</xref>).[<xref ref-type="bibr" rid="pone.0182376.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0182376.ref009">9</xref>] Forty references consisting of pure HIV-1 subtype and main circulating recombinant forms (CRFs) were used to identify and designate HIV-1 subtypes (<xref ref-type="supplementary-material" rid="pone.0182376.s004">S1 Table</xref>). Recombinant subtype analysis was performed using a combination of HIV-1 Genotyping Tool[<xref ref-type="bibr" rid="pone.0182376.ref010">10</xref>], Jumping Profile Hidden Markov model [<xref ref-type="bibr" rid="pone.0182376.ref011">11</xref>], visual inspection, and construction of subregion ML trees with bootstrap analyses to confirm breakpoint assignments. Bootstrap values of 95 percent or higher and a genetic distance cutoff value of ≤1.5% (≤0.015 nucleotide substitutions per site) were used to identify sequences that were highly related to each other (i.e. a cluster). The cutoff value was established by identifying an optimal intra-cluster genetic distance using available sequences for all Soldiers (<xref ref-type="supplementary-material" rid="pone.0182376.s002">S2 Fig</xref>). The Tamura-Nei 93 distance model was used as well to confirm sequence relatedness and showed no significant differences from the K2P model (<xref ref-type="supplementary-material" rid="pone.0182376.s003">S3 Fig</xref>). Transmitted drug resistance mutations were identified using the World Health Organization’s 2009 standard surveillance list available from the Stanford HIV database; any resistance to non-/nucleoside reverse transcriptase or protease inhibitor resistance was considered.</p>
</sec>
<sec id="sec012">
<title>Analysis</title>
<p>Demographics (age, self-reported race, sex, occupation, pay grade, service rank) and other characteristics (location of assignment, STI co-infection, HIV specialty care: CD3/CD4, viral load, antiretroviral resistance testing, antiretroviral treatment) at/proximal to diagnosis were evaluated for all HIV-infected Soldiers and compared for those who were linked in transmission clusters to those who were not. Only transmission clusters for the study population (Soldiers in active service only and not the reserve component) were selected for further univariate and multivariate analysis; sequence data, demographic and other characteristics of interest were either not available or incomplete for HIV-infected Soldiers who were not in active service. Univariate and multivariate logistic regression models were used to evaluate, and adjust for, the association between characteristics and cluster membership. In general, sub-categories having lower risk (or normative sub-categories) were chosen as reference levels in multivariate analysis. Data were managed and analyzed using Statistical Analysis Software version 9.3 (SAS Cary, North Carolina).</p>
</sec>
</sec>
<sec id="sec013" sec-type="results">
<title>Results</title>
<sec id="sec014">
<title>Study population</title>
<p>A total of 995 Soldiers in active service were newly-diagnosed with HIV-1 from January 1, 2001 through December 31, 2012. A majority (97%) were male, of non-white race (74%), with a median age of 27.0 years (interquartile range (IQR) 23.0–35.0) (<xref ref-type="table" rid="pone.0182376.t001">Table 1</xref>). At diagnosis, 64% were assigned to a duty station in the southern U.S., 37% had a seronegative HIV test within the past year (median 437.0 days, IQR 258.0–702.5 days), and 52% had been in service for 5 years or less (median 5.0, IQR 2.0–11.0). Ninety percent (n = 896) of HIV-infected Soldiers had evidence of HIV specialty care within a median 35 days (IQR 18.0–58.0) of diagnosis. Almost half (43%) of HIV-infected Soldiers had a viral load of 10,000 copies/ml or more (median 21503.5, IQR 4888.0–69317.0; CD3/CD4 (cells/μl) median 445 (IQR 330.0–593.0)) (<xref ref-type="table" rid="pone.0182376.t001">Table 1</xref>).</p>
<table-wrap id="pone.0182376.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182376.t001</object-id>
<label>Table 1</label> <caption><title>Demographic, service-related, and clinical characteristics of 995 HIV-infected Soldiers newly diagnosed from 2001–2012, overall, and by transmission clustering.</title></caption>
<alternatives>
<graphic id="pone.0182376.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" style="background-color:#C5D9F1">Characteristic at Diagnosis</th>
<th align="left" style="background-color:#C5D9F1">Value</th>
<th align="center" colspan="2" style="background-color:#C5D9F1">All Cases<break/>n = 995</th>
<th align="center" colspan="2" style="background-color:#C5D9F1">Clustered<break/>n = 151</th>
<th align="center" colspan="2" style="background-color:#C5D9F1">Not Clustered<break/>n = 367</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age (years)</td>
<td align="left">18–20</td>
<td align="right">71</td>
<td align="left">(7)</td>
<td align="right">14</td>
<td align="left">(9)</td>
<td align="right">20</td>
<td align="left">(5)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">21–24</td>
<td align="right">275</td>
<td align="left">(28)</td>
<td align="right">47</td>
<td align="left">(31)</td>
<td align="right">100</td>
<td align="left">(27)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">25–29</td>
<td align="right">254</td>
<td align="left">(25)</td>
<td align="right">43</td>
<td align="left">(28)</td>
<td align="right">107</td>
<td align="left">(29)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">30–34</td>
<td align="right">140</td>
<td align="left">(14)</td>
<td align="right">18</td>
<td align="left">(12)</td>
<td align="right">55</td>
<td align="left">(15)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">35–39</td>
<td align="right">111</td>
<td align="left">(11)</td>
<td align="right">18</td>
<td align="left">(12)</td>
<td align="right">36</td>
<td align="left">(10)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">40+</td>
<td align="right">144</td>
<td align="left">(14)</td>
<td align="right">11</td>
<td align="left">(7)</td>
<td align="right">49</td>
<td align="left">(13)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Race, ethnicity</td>
<td align="left" style="background-color:#DCE6F1">White, non-Hispanic</td>
<td align="right" style="background-color:#DCE6F1">260</td>
<td align="left" style="background-color:#DCE6F1">(26)</td>
<td align="right" style="background-color:#DCE6F1">27</td>
<td align="left" style="background-color:#DCE6F1">(18)</td>
<td align="right" style="background-color:#DCE6F1">98</td>
<td align="left" style="background-color:#DCE6F1">(27)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Black, non-Hispanic</td>
<td align="right">583</td>
<td align="left">(59)</td>
<td align="right">103</td>
<td align="left">(68)</td>
<td align="right">210</td>
<td align="left">(57)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Other</td>
<td align="right">152</td>
<td align="left">(15)</td>
<td align="right">21</td>
<td align="left">(14)</td>
<td align="right">59</td>
<td align="left">(16)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Sex</td>
<td align="left" style="background-color:#DCE6F1">Male</td>
<td align="right" style="background-color:#DCE6F1">964</td>
<td align="left" style="background-color:#DCE6F1">(97)</td>
<td align="right" style="background-color:#DCE6F1">148</td>
<td align="left" style="background-color:#DCE6F1">(98)</td>
<td align="right" style="background-color:#DCE6F1">359</td>
<td align="left" style="background-color:#DCE6F1">(98)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Female</td>
<td align="right">31</td>
<td align="left">(3)</td>
<td align="right">3</td>
<td align="left">(2)</td>
<td align="right">8</td>
<td align="left">(2)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Marital status</td>
<td align="left" style="background-color:#DCE6F1">Single</td>
<td align="right" style="background-color:#DCE6F1">563</td>
<td align="left" style="background-color:#DCE6F1">(57)</td>
<td align="right" style="background-color:#DCE6F1">85</td>
<td align="left" style="background-color:#DCE6F1">(56)</td>
<td align="right" style="background-color:#DCE6F1">215</td>
<td align="left" style="background-color:#DCE6F1">(59)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Married</td>
<td align="right">369</td>
<td align="left">(37)</td>
<td align="right">59</td>
<td align="left">(39)</td>
<td align="right">130</td>
<td align="left">(35)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Other</td>
<td align="right">52</td>
<td align="left">(5)</td>
<td align="right">7</td>
<td align="left">(5)</td>
<td align="right">18</td>
<td align="left">(5)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Highest education attained</td>
<td align="left" style="background-color:#DCE6F1">High school or less</td>
<td align="right" style="background-color:#DCE6F1">744</td>
<td align="left" style="background-color:#DCE6F1">(75)</td>
<td align="right" style="background-color:#DCE6F1">121</td>
<td align="left" style="background-color:#DCE6F1">(80)</td>
<td align="right" style="background-color:#DCE6F1">272</td>
<td align="left" style="background-color:#DCE6F1">(74)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Some college or more</td>
<td align="right">212</td>
<td align="left">(21)</td>
<td align="right">28</td>
<td align="left">(18)</td>
<td align="right">83</td>
<td align="left">(23)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Length of service</td>
<td align="left" style="background-color:#DCE6F1">1–2</td>
<td align="right" style="background-color:#DCE6F1">259</td>
<td align="left" style="background-color:#DCE6F1">(26)</td>
<td align="right" style="background-color:#DCE6F1">40</td>
<td align="left" style="background-color:#DCE6F1">(26)</td>
<td align="right" style="background-color:#DCE6F1">98</td>
<td align="left" style="background-color:#DCE6F1">(27)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">3–5</td>
<td align="right">259</td>
<td align="left">(26)</td>
<td align="right">40</td>
<td align="left">(26)</td>
<td align="right">87</td>
<td align="left">(24)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">6–8</td>
<td align="right">142</td>
<td align="left">(14)</td>
<td align="right">28</td>
<td align="left">(18)</td>
<td align="right">65</td>
<td align="left">(18)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">9+</td>
<td align="right">331</td>
<td align="left">(33)</td>
<td align="right">43</td>
<td align="left">(28)</td>
<td align="right">117</td>
<td align="left">(32)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Pay grade</td>
<td align="left" style="background-color:#DCE6F1">E1-E4</td>
<td align="right" style="background-color:#DCE6F1">497</td>
<td align="left" style="background-color:#DCE6F1">(50)</td>
<td align="right" style="background-color:#DCE6F1">72</td>
<td align="left" style="background-color:#DCE6F1">(48)</td>
<td align="right" style="background-color:#DCE6F1">173</td>
<td align="left" style="background-color:#DCE6F1">(47)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">E5-E9</td>
<td align="right">386</td>
<td align="left">(39)</td>
<td align="right">68</td>
<td align="left">(45)</td>
<td align="right">148</td>
<td align="left">(40)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Officer</td>
<td align="right">104</td>
<td align="left">(10)</td>
<td align="right">11</td>
<td align="left">(7)</td>
<td align="right">43</td>
<td align="left">(12)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Occupation category</td>
<td align="left" style="background-color:#DCE6F1">Combat</td>
<td align="right" style="background-color:#DCE6F1">147</td>
<td align="left" style="background-color:#DCE6F1">(15)</td>
<td align="right" style="background-color:#DCE6F1">31</td>
<td align="left" style="background-color:#DCE6F1">(20)</td>
<td align="right" style="background-color:#DCE6F1">52</td>
<td align="left" style="background-color:#DCE6F1">(14)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Health Care</td>
<td align="right">131</td>
<td align="left">(13)</td>
<td align="right">15</td>
<td align="left">(10)</td>
<td align="right">51</td>
<td align="left">(14)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Other</td>
<td align="right">717</td>
<td align="left">(72)</td>
<td align="right">105</td>
<td align="left">(69)</td>
<td align="right">264</td>
<td align="left">(72)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Calendar year</td>
<td align="left" style="background-color:#DCE6F1">2001</td>
<td align="right" style="background-color:#DCE6F1">67</td>
<td align="left" style="background-color:#DCE6F1">(7)</td>
<td align="right" style="background-color:#DCE6F1">1</td>
<td align="left" style="background-color:#DCE6F1">(1)</td>
<td align="right" style="background-color:#DCE6F1">10</td>
<td align="left" style="background-color:#DCE6F1">(3)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2002</td>
<td align="right">68</td>
<td align="left">(7)</td>
<td align="right">0</td>
<td align="left">(0)</td>
<td align="right">12</td>
<td align="left">(3)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2003</td>
<td align="right">78</td>
<td align="left">(8)</td>
<td align="right">1</td>
<td align="left">(1)</td>
<td align="right">15</td>
<td align="left">(4)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2004</td>
<td align="right">64</td>
<td align="left">(6)</td>
<td align="right">2</td>
<td align="left">(1)</td>
<td align="right">18</td>
<td align="left">(5)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2005</td>
<td align="right">71</td>
<td align="left">(7)</td>
<td align="right">5</td>
<td align="left">(3)</td>
<td align="right">16</td>
<td align="left">(4)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2006</td>
<td align="right">70</td>
<td align="left">(7)</td>
<td align="right">12</td>
<td align="left">(8)</td>
<td align="right">15</td>
<td align="left">(4)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2007</td>
<td align="right">70</td>
<td align="left">(7)</td>
<td align="right">15</td>
<td align="left">(10)</td>
<td align="right">31</td>
<td align="left">(8)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2008</td>
<td align="right">103</td>
<td align="left">(10)</td>
<td align="right">22</td>
<td align="left">(15)</td>
<td align="right">52</td>
<td align="left">(14)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2009</td>
<td align="right">93</td>
<td align="left">(9)</td>
<td align="right">12</td>
<td align="left">(8)</td>
<td align="right">47</td>
<td align="left">(13)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2010</td>
<td align="right">95</td>
<td align="left">(10)</td>
<td align="right">20</td>
<td align="left">(13)</td>
<td align="right">36</td>
<td align="left">(10)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2011</td>
<td align="right">105</td>
<td align="left">(11)</td>
<td align="right">23</td>
<td align="left">(15)</td>
<td align="right">57</td>
<td align="left">(15)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">2012</td>
<td align="right">111</td>
<td align="left">(11)</td>
<td align="right">38</td>
<td align="left">(25)</td>
<td align="right">58</td>
<td align="left">(16)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Assignment location, region<xref ref-type="table-fn" rid="t001fn002">*</xref></td>
<td align="left" style="background-color:#DCE6F1">South</td>
<td align="right" style="background-color:#DCE6F1">633</td>
<td align="left" style="background-color:#DCE6F1">(64)</td>
<td align="right" style="background-color:#DCE6F1">118</td>
<td align="left" style="background-color:#DCE6F1">(78)</td>
<td align="right" style="background-color:#DCE6F1">223</td>
<td align="left" style="background-color:#DCE6F1">(61)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">West</td>
<td align="right">149</td>
<td align="left">(15)</td>
<td align="right">22</td>
<td align="left">(14)</td>
<td align="right">51</td>
<td align="left">(14)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Non-US</td>
<td align="right">116</td>
<td align="left">(12)</td>
<td align="right">7</td>
<td align="left">(5)</td>
<td align="right">58</td>
<td align="left">(16)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Midwest</td>
<td align="right">46</td>
<td align="left">(5)</td>
<td align="right">4</td>
<td align="left">(3)</td>
<td align="right">23</td>
<td align="left">(6)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Northeast</td>
<td align="right">13</td>
<td align="left">(1)</td>
<td align="right">0</td>
<td align="left">(0)</td>
<td align="right">5</td>
<td align="left">(1)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Territory</td>
<td align="right">3</td>
<td align="left">(0)</td>
<td align="right">0</td>
<td align="left">(0)</td>
<td align="right">1</td>
<td align="left">(0)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">CD3 CD4, absolute (cells/μl)</td>
<td align="left" style="background-color:#DCE6F1">249 or less</td>
<td align="right" style="background-color:#DCE6F1">91</td>
<td align="left" style="background-color:#DCE6F1">(9)</td>
<td align="right" style="background-color:#DCE6F1">10</td>
<td align="left" style="background-color:#DCE6F1">(7)</td>
<td align="right" style="background-color:#DCE6F1">34</td>
<td align="left" style="background-color:#DCE6F1">(9)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">250–500</td>
<td align="right">404</td>
<td align="left">(41)</td>
<td align="right">74</td>
<td align="left">(49)</td>
<td align="right">151</td>
<td align="left">(41)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">501–1979</td>
<td align="right">390</td>
<td align="left">(39)</td>
<td align="right">63</td>
<td align="left">(42)</td>
<td align="right">172</td>
<td align="left">(47)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Viral load</td>
<td align="left" style="background-color:#DCE6F1">&lt;10k</td>
<td align="right" style="background-color:#DCE6F1">228</td>
<td align="left" style="background-color:#DCE6F1">(23)</td>
<td align="right" style="background-color:#DCE6F1">33</td>
<td align="left" style="background-color:#DCE6F1">(22)</td>
<td align="right" style="background-color:#DCE6F1">100</td>
<td align="left" style="background-color:#DCE6F1">(27)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">10-99k</td>
<td align="right">313</td>
<td align="left">(31)</td>
<td align="right">74</td>
<td align="left">(49)</td>
<td align="right">150</td>
<td align="left">(41)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">&gt;100k</td>
<td align="right">115</td>
<td align="left">(12)</td>
<td align="right">23</td>
<td align="left">(15)</td>
<td align="right">51</td>
<td align="left">(14)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Any STI</td>
<td align="left" style="background-color:#DCE6F1">Yes</td>
<td align="right" style="background-color:#DCE6F1">136/848</td>
<td align="left" style="background-color:#DCE6F1">(14)</td>
<td align="right" style="background-color:#DCE6F1">34/148</td>
<td align="left" style="background-color:#DCE6F1">(22)</td>
<td align="right" style="background-color:#DCE6F1">54/352</td>
<td align="left" style="background-color:#DCE6F1">(15)</td>
</tr>
<tr>
<td align="left">    Hepatitis B, acute</td>
<td align="left">Yes</td>
<td align="right">5/719</td>
<td align="left">(0)</td>
<td align="right">1/135</td>
<td align="left">(1)</td>
<td align="right">1/303</td>
<td align="left">(0)</td>
</tr>
<tr>
<td align="left">    Hepatitis C, chronic</td>
<td align="left">Yes</td>
<td align="right">6/723</td>
<td align="left">(1)</td>
<td align="right">1/139</td>
<td align="left">(1)</td>
<td align="right">1/299</td>
<td align="left">(0)</td>
</tr>
<tr>
<td align="left">    Syphilis</td>
<td align="left">Yes</td>
<td align="right">85/591</td>
<td align="left">(8)</td>
<td align="right">19/116</td>
<td align="left">(12)</td>
<td align="right">38/243</td>
<td align="left">(11)</td>
</tr>
<tr>
<td align="left">    <italic>Neisseria gonorrhea</italic></td>
<td align="left">Yes</td>
<td align="right">22/435</td>
<td align="left">(2)</td>
<td align="right">7/108</td>
<td align="left">(4)</td>
<td align="right">7/203</td>
<td align="left">(2)</td>
</tr>
<tr>
<td align="left">    <italic>Chlamydia trachomatis</italic></td>
<td align="left">Yes</td>
<td align="right">36/435</td>
<td align="left">(4)</td>
<td align="right">15/107</td>
<td align="left">(9)</td>
<td align="right">12/205</td>
<td align="left">(3)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Last HIV test (days)</td>
<td align="left" style="background-color:#DCE6F1">&lt;180</td>
<td align="right" style="background-color:#DCE6F1">143</td>
<td align="left" style="background-color:#DCE6F1">(14)</td>
<td align="right" style="background-color:#DCE6F1">26</td>
<td align="left" style="background-color:#DCE6F1">(17)</td>
<td align="right" style="background-color:#DCE6F1">46</td>
<td align="left" style="background-color:#DCE6F1">(12)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">181–365</td>
<td align="right">234</td>
<td align="left">(23)</td>
<td align="right">35</td>
<td align="left">(23)</td>
<td align="right">101</td>
<td align="left">(27)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">366–730</td>
<td align="right">393</td>
<td align="left">(39)</td>
<td align="right">77</td>
<td align="left">(51)</td>
<td align="right">160</td>
<td align="left">(44)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">&gt;730</td>
<td align="right">214</td>
<td align="left">(21)</td>
<td align="right">13</td>
<td align="left">(9)</td>
<td align="right">58</td>
<td align="left">(16)</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">ART naïve<xref ref-type="table-fn" rid="t001fn003"><sup>†</sup></xref></td>
<td align="left" style="background-color:#DCE6F1">Yes</td>
<td align="right" style="background-color:#DCE6F1">400/443</td>
<td align="left" style="background-color:#DCE6F1">(40)</td>
<td align="right" style="background-color:#DCE6F1">127/132</td>
<td align="left" style="background-color:#DCE6F1">(84)</td>
<td align="right" style="background-color:#DCE6F1">273/311</td>
<td align="left" style="background-color:#DCE6F1">(74)</td>
</tr>
<tr>
<td align="left">Transmitted drug resistance</td>
<td align="left">Yes</td>
<td align="right">155/518</td>
<td align="left">(16)</td>
<td align="right">54/151</td>
<td align="left">(36)</td>
<td align="right">101/367</td>
<td align="left">(27)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Notes: n (%) unless otherwise indicated; missing values are not shown.</p></fn>
<fn id="t001fn002"><p>*States were categorized into region using U.S. Census Bureau definitions; the Southern U.S. includes Alabama, Arkansas, Delaware, Florida, Georgia, Louisiana, Kentucky, Maryland, Mississippi, Oklahoma, North Carolina, South Carolina, Tennessee, Texas, Virginia, West Virginia, and the District of Columbia</p></fn>
<fn id="t001fn003"><p><sup>†</sup>Among those with documented evidence of antiretroviral prescriptions (n = 441), for 9% who had no sequence on file before ART was initiated, the next available sequence after ART initiation was used in analysis.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Among HIV-infected Soldiers, 518 (52%) had a partial <italic>pol</italic> sequence available for analysis. A majority (79%) of sequences were generated after 2006 and a median 50 days (IQR 27.0–257.0) post-diagnosis. Subtyping of the <italic>pol</italic> fragment indicated HIV-1 subtype B infection predominated among HIV-infected Soldiers (94%); non-B subtypes identified were A (1%), C (1%), G (1%) and inter-subtype recombinants (3%: AB, AD, BC, and CRF02/B– 0.2% each, CRF01–0.6%, CRF02–1.2%). Among antiretroviral therapy (ART)-naïve Soldiers with subtype B infection (n = 374), resistance to non-nucleoside reverse transcriptase inhibitor drugs was most common (22%) followed by resistance to nucleoside reverse transcriptase inhibitor (7%) and major protease inhibitors (3%). We classified 29% (47 pairs, 16 non-pairs) of sequences as being clustered; 96% were subtype B infections and remaining subtypes were A (1.3%), C (1.3%), and G (1.3%). Clusters were composed of a median of 2 members (IQR 2.0–3.0, mean 2.4, range 2.0–6.0).</p>
</sec>
<sec id="sec015">
<title>Characteristics of membership in transmission clusters</title>
<p>In univariate analysis, HIV-infected Soldiers with membership in a cluster were slightly younger (mean 28 vs 29), more frequently of black, non-Hispanic racial and ethnic origin (68% vs 57%), differed in calendar year and duty location of diagnosis, were more likely to have a STI co-infection (22% vs.15%), less frequently initiated ART (84% vs 74%), and differed in HIV-1 TDR resistance (36% vs 27%) compared to Soldiers who were not part of a transmission pair/cluster (p≤0.05, <xref ref-type="table" rid="pone.0182376.t001">Table 1</xref>). Among those who were clustered, 98% were linked to other male Soldiers; of the 2% who were not, 2 female Soldiers were linked to each other and were of black or other race, and 1 female was linked to a male Soldier (both were of black race). Of black, non-Hispanic Soldiers in clusters, 69% were linked to other black Soldiers and of white, non-Hispanic Soldiers, 26% were linked to other white Soldiers while 59% were linked to black Soldiers. Among 5 Soldiers who were ART experienced, and who were all members of transmission pairs, 3 had HIV-1 sequences with a TDR mutation; the other members of the pairs were ART naïve with HIV-1 sequences having no TDR mutations. Transmitted drug mutations were found more commonly among clusters with a membership size of 3 or more (member n = 32, 59%) compared to transmission pairs (member n = 22, 41%).</p>
<p>In multivariate analysis, after adjustment for other significant characteristics (p&lt;0.10), only two factors were associated independently with cluster membership (<xref ref-type="table" rid="pone.0182376.t002">Table 2</xref>). Soldiers assigned to a southern region at diagnosis were almost twice as likely to be part of a transmission cluster compared with Soldiers assigned elsewhere [adjusted odds ratio (AOR) 1.94, 95% confidence interval (95% C.I.) 1.19–3.18]. The odds of having membership in a transmission network increased 12% for each calendar year of HIV diagnosis (AOR 1.12, 95% C.I. 1.03–1.23).</p>
<table-wrap id="pone.0182376.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182376.t002</object-id>
<label>Table 2</label> <caption><title>Characteristics of 518 newly diagnosed HIV-infected Soldiers associated with transmission clustering, 2001–2012.</title></caption>
<alternatives>
<graphic id="pone.0182376.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" style="background-color:#C5D9F1">Characteristic at diagnosis</th>
<th align="left" style="background-color:#C5D9F1">Value</th>
<th align="left" style="background-color:#C5D9F1">Unadjusted OR</th>
<th align="left" style="background-color:#C5D9F1">95% C.I.</th>
<th align="left" style="background-color:#C5D9F1">P-value</th>
<th align="left" style="background-color:#C5D9F1">Adjusted OR<xref ref-type="table-fn" rid="t002fn001">*</xref></th>
<th align="left" style="background-color:#C5D9F1">95% C.I.</th>
<th align="center" style="background-color:#C5D9F1">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age (years)</td>
<td align="left">One year</td>
<td align="right">0.97</td>
<td align="left">(0.95–0.99)</td>
<td align="left">0.040</td>
<td align="right">0.98</td>
<td align="left">(0.94–1.01)</td>
<td align="center">0.143</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Race, ethnicity</td>
<td align="left" style="background-color:#DCE6F1">Black, non-Hispanic/Other vs White, non-Hispanic</td>
<td align="right" style="background-color:#DCE6F1">1.67</td>
<td align="left" style="background-color:#DCE6F1">(1.04–2.69)</td>
<td align="left" style="background-color:#DCE6F1">0.034</td>
<td align="right" style="background-color:#DCE6F1">1.60</td>
<td align="left" style="background-color:#DCE6F1">(0.91–2.81)</td>
<td align="center" style="background-color:#DCE6F1">0.103</td>
</tr>
<tr>
<td align="left">Marital status</td>
<td align="left">Single vs non-single</td>
<td align="right">0.89</td>
<td align="left">(0.60–1.30)</td>
<td align="left">0.538</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Education</td>
<td align="left" style="background-color:#DCE6F1">High school or less vs Some college or more</td>
<td align="right" style="background-color:#DCE6F1">1.32</td>
<td align="left" style="background-color:#DCE6F1">(0.82–2.13)</td>
<td align="left" style="background-color:#DCE6F1">0.258</td>
<td align="right" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
</tr>
<tr>
<td align="left">Grade</td>
<td align="left">E1-E4 vs Officer</td>
<td align="right">1.63</td>
<td align="left">(0.79–3.33)</td>
<td align="left">0.184</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">E5-E9 vs Officer</td>
<td align="right">1.80</td>
<td align="left">(0.87–3.70)</td>
<td align="left">0.112</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Length in service (years)</td>
<td align="left" style="background-color:#DCE6F1">One year</td>
<td align="right" style="background-color:#DCE6F1">0.98</td>
<td align="left" style="background-color:#DCE6F1">(0.95–1.01)</td>
<td align="left" style="background-color:#DCE6F1">0.225</td>
<td align="right" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
</tr>
<tr>
<td align="left">Occupation category</td>
<td align="left">Combat vs Other</td>
<td align="right">1.50</td>
<td align="left">(0.91–2.47)</td>
<td align="left">0.112</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Health Care vs Other</td>
<td align="right">0.74</td>
<td align="left">(0.40–1.37)</td>
<td align="left">0.339</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Calendar year</td>
<td align="left" style="background-color:#DCE6F1">One year</td>
<td align="right" style="background-color:#DCE6F1">1.13</td>
<td align="left" style="background-color:#DCE6F1">(1.06–1.22)</td>
<td align="left" style="background-color:#DCE6F1">0.001</td>
<td align="right" style="background-color:#DCE6F1">1.12</td>
<td align="left" style="background-color:#DCE6F1">(1.03–1.23)</td>
<td align="center" style="background-color:#DCE6F1">0.013</td>
</tr>
<tr>
<td align="left">Assignment location (region)</td>
<td align="left">South vs Other</td>
<td align="right">2.21</td>
<td align="left">(1.42–3.44)</td>
<td align="left">0.000</td>
<td align="right">1.94</td>
<td align="left">(1.19–3.18)</td>
<td align="center">0.008</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">CD3 CD4 (cells/μl)</td>
<td align="left" style="background-color:#DCE6F1">100 cells</td>
<td align="right" style="background-color:#DCE6F1">0.97</td>
<td align="left" style="background-color:#DCE6F1">(0.89–1.06)</td>
<td align="left" style="background-color:#DCE6F1">0.478</td>
<td align="right" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
<td align="center" style="background-color:#DCE6F1">-</td>
</tr>
<tr>
<td align="left">Viral load (copies/mL)</td>
<td align="left">&lt;10,000 vs. &gt;100,000</td>
<td align="right">0.73</td>
<td align="left">(0.39–1.37)</td>
<td align="left">0.331</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">10,000–99,999 vs &gt;100,000</td>
<td align="right">1.09</td>
<td align="left">(0.62–1.93)</td>
<td align="left">0.756</td>
<td align="right">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">Any STI</td>
<td align="left" style="background-color:#DCE6F1">Yes vs No</td>
<td align="right" style="background-color:#DCE6F1">1.65</td>
<td align="left" style="background-color:#DCE6F1">(1.02–2.66)</td>
<td align="left" style="background-color:#DCE6F1">0.042</td>
<td align="right" style="background-color:#DCE6F1">1.45</td>
<td align="left" style="background-color:#DCE6F1">(0.84–2.51)</td>
<td align="center" style="background-color:#DCE6F1">0.177</td>
</tr>
<tr>
<td align="left">Last negative test (months)</td>
<td align="left">One month</td>
<td align="right">0.98</td>
<td align="left">(0.96–1.00)</td>
<td align="left">0.044</td>
<td align="right">0.99</td>
<td align="left">(0.97–1.00)</td>
<td align="center">0.145</td>
</tr>
<tr>
<td align="left" style="background-color:#DCE6F1">ART naïve</td>
<td align="left" style="background-color:#DCE6F1">Yes vs No</td>
<td align="right" style="background-color:#DCE6F1">3.53</td>
<td align="left" style="background-color:#DCE6F1">(1.36–9.19)</td>
<td align="left" style="background-color:#DCE6F1">0.010</td>
<td align="right" style="background-color:#DCE6F1">2.82</td>
<td align="left" style="background-color:#DCE6F1">(0.89–8.92)</td>
<td align="center" style="background-color:#DCE6F1">0.077</td>
</tr>
<tr>
<td align="left">Transmitted drug resistance</td>
<td align="left">Yes vs No</td>
<td align="right">1.47</td>
<td align="left">(0.98–2.20)</td>
<td align="left">0.060</td>
<td align="right">1.55</td>
<td align="left">(0.97–2.48)</td>
<td align="center">0.069</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>*Variables were adjusted for characteristics of significance (p-value&lt;0.10) in univariate analysis.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec016" sec-type="conclusions">
<title>Discussion</title>
<p>We evaluated demographic and clinical characteristics of 995 active duty Soldiers newly diagnosed with HIV from 2001 to 2012 and explored characteristics associated with membership in transmission clusters among 518 HIV-infected Soldiers with partial <italic>pol</italic> sequences. More than a third had an HIV diagnosis within one year of the last negative HIV test and a significant proportion of Soldiers had received HIV specialty care within 3 months of HIV diagnosis. Subtype B infection predominated (94%) similar to HIV-1 infections identified by the NHSS in the U.S. (93.3%).[<xref ref-type="bibr" rid="pone.0182376.ref012">12</xref>] Among 29% of Soldiers who were members of transmission clusters, two characteristics were associated independently with clustering: assignment to a southern U.S. location at diagnosis and year of diagnosis.</p>
<p>Several factors that increase HIV acquisition and transmission may explain the association between duty assignment and cluster membership. U.S. national surveillance data from 2008 to 2012 indicated that southern states had the highest diagnosis rate of HIV, especially among nine states (Alabama, Florida, Georgia, Louisiana, Mississippi, North and South Carolina, Tennessee and Texas) referred to as the Deep South, and the highest HIV-related death rate even after adjustment for factors at diagnosis such as age, race, sex, transmission category and residence indicating that factors other than these were influential in HIV outcomes.[<xref ref-type="bibr" rid="pone.0182376.ref013">13</xref>] Influential factors may include low state population density of lesbian, gay, bisexual, and transgender individuals, income inequality, high syphilis rates, insufficient or delayed access to health care including testing for HIV, and receiving HIV care (only 30% with HIV were virally suppressed in 2011), lack of awareness of HIV infection status, poor overall health, and HIV-related stigma.[<xref ref-type="bibr" rid="pone.0182376.ref014">14</xref>–<xref ref-type="bibr" rid="pone.0182376.ref016">16</xref>] Although the U.S. HIV diagnosis rate decreased from 2005 to 2014, the rate increased among black/African American MSM,[<xref ref-type="bibr" rid="pone.0182376.ref017">17</xref>] especially among black MSM in the South, who accounted for more than half of HIV diagnoses in 2014.[<xref ref-type="bibr" rid="pone.0182376.ref018">18</xref>] Assignment in the South may have increased the likelihood of HIV acquisition especially among black/African American Soldiers. Recent Army HIV behavioral surveillance data indicate that a majority of HIV-infected Soldiers were black/African American and MSM who believed they acquired HIV in southern U.S. states.[<xref ref-type="bibr" rid="pone.0182376.ref004">4</xref>] Among MSM, 64% reported having civilian partners and 36%, service member partners. Black/African American HIV-infected men in the U.S. were more likely to be linked to partners of the same race than white HIV-infected men (81% versus 62%, respectively).[<xref ref-type="bibr" rid="pone.0182376.ref003">3</xref>]</p>
<p>Increasing calendar year of HIV diagnosis was associated independently with cluster membership. Although it is likely surveillance or sampling bias may have increased the likelihood of detecting transmission networks as more sequence data accumulated over time due to increased antiretroviral testing from compliance with national guidelines for earlier initiation of ART,[<xref ref-type="bibr" rid="pone.0182376.ref019">19</xref>] characteristics of the national HIV epidemic may also explain the association. National HIV data indicated a predicted increase in incidence in the U.S. since 2001 with an estimated 50,000 infections occurring nationally each year.[<xref ref-type="bibr" rid="pone.0182376.ref020">20</xref>] Contributors to forward transmission included lack of awareness of HIV infection status in up to one-fifth of those infected and less than half of the HIV-infected population on antiretroviral therapy in 2011 with the lowest proportion of viral suppression among those aged 18–34 years.[<xref ref-type="bibr" rid="pone.0182376.ref014">14</xref>] It is likely that the same contributory factors for transmission in the national HIV epidemic are impacting the military HIV epidemic. Recent interview data from HIV-infected Soldiers indicate epidemiological linkage with members of the national civilian population.[<xref ref-type="bibr" rid="pone.0182376.ref004">4</xref>] Army regulations mandate force-wide biennial HIV testing.[<xref ref-type="bibr" rid="pone.0182376.ref021">21</xref>] However, our analysis indicates more than a third of HIV-infected Soldiers (and more than half of Soldiers who were clustered) could have benefited from annual, rather than biennial, testing and subsequent earlier linkage to specialty care due to earlier diagnosis. CDC’s 2006 guidelines recommend at least annual testing among high-risk persons.[<xref ref-type="bibr" rid="pone.0182376.ref022">22</xref>] Furthermore, studies indicate that testing high risk persons (populations with ≥1.0% incidence) every three months is cost-effective.[<xref ref-type="bibr" rid="pone.0182376.ref023">23</xref>, <xref ref-type="bibr" rid="pone.0182376.ref024">24</xref>] One such study which evaluated testing intervals using fourth-generation assays among MSM found even more frequent testing such as quarterly or biannual testing was cost effective compared to annual testing.[<xref ref-type="bibr" rid="pone.0182376.ref023">23</xref>]</p>
<p>These analyses had limitations. The transmission clusters that were observed do not indicate the direction of transmission or actual transmission events since un-sampled individuals may be involved. Furthermore, the strict criteria that we used to define clustering as well as undersampling of the infected population may have led to an underestimation of the magnitude of clustering among HIV-infected Soldiers.</p>
<p>In conclusion, despite unavailability of sequences for a large proportion of HIV-infected Soldiers and use of strict criteria for identifying clusters, we effectively utilized routinely available clinical sequence data in HIV surveillance to identify factors associated with cluster membership. These findings corroborate recent behavioral surveillance data and indicate that further study of transmission networks using military enterprise-wide sequence coverage and transmission category data are warranted as well as a renewed cost analyses of targeted HIV prevention efforts. An increased frequency of current force testing may be justified, especially among Soldiers assigned to duty in installations with high local HIV prevalence such as southern U.S. states.</p>
</sec>
<sec id="sec017">
<title>Supporting information</title>
<supplementary-material id="pone.0182376.s001" mimetype="application/jpeg" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Phylogenetic tree of assignment of viral subtypes and significant transmission clusters.</title>
<p>A phylogenetic analysis of viral subtypes, with respect to 40 reference sequences, and significant transmission clusters using the maximum likelihood method in MEGA6. The subtypes are denoted by purple, blue, and green arcs. The transmission clusters with bootstrap values of ≥95% and genetic distances of ≤1.5% are illustrated as red dots.</p>
<p>(JPG)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182376.s002" mimetype="application/jpeg" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>The distribution of pair-wise distances between clustered sequences compared to all sequences.</title>
<p>The histogram depicts the distribution of pair-wise distances between clustered sequences compared to all sequences.</p>
<p>(JPG)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182376.s003" mimetype="application/jpeg" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Comparison of genetic distances generated using two pair-wise distance models.</title>
<p>A comparison of genetic distances generated using two pair-wise distance models, Kimura’s two parameter (1980) and Tamura-Nei (1993) (Pearson product-moment correlation coefficient = 0.999)</p>
<p>(JPG)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182376.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0182376.s004" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>List of forty reference sequences that were used for subtyping in phylogenetic analysis.</title>
<p>Forty references consisting of pure HIV-1 subtype and main circulating recombinant forms.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>Disclaimer <bold>“</bold>The views expressed are those of the authors and should not be construed to represent the position of the U.S. Department of the Army or Defense.“</p>
<p>We thank Christine Walsh, Wesley Robb-McGrath, Amanda McIntrye, and Bruno Petruccelli for their efforts in clinical data collection. We are grateful to Goldwynn Manabat and Amanda McIntyre for their assistance in data entry.</p>
<p>This work was supported by the U.S. Army Medical Research and Materiel Command under Contract No W81XWH-16-C-0225 and by a cooperative agreement (W81XWH-11-2-0174) between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and the U.S. Department of Defense (DoD).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0182376.ref001"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Office of the Press Secretary USW. FACT SHEET: The National HIV/AIDS Strategy: Updated to 2020 2015 [cited 2016 August 18, 2016]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.whitehouse.gov/the-press-office/2015/07/30/fact-sheet-national-hivaids-strategy-updated-2020" xlink:type="simple">https://www.whitehouse.gov/the-press-office/2015/07/30/fact-sheet-national-hivaids-strategy-updated-2020</ext-link>.</mixed-citation></ref>
<ref id="pone.0182376.ref002"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Centers for Disease Control and Prevention. Selected National HIV Prevention and Care Outcomes in the United States 2016 [cited 2016 August 18, 2016]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-national-hiv-care-outcomes.pdf" xlink:type="simple">https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-national-hiv-care-outcomes.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0182376.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oster</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Wertheim</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Hernandez</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Ocfemia</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Saduvala</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hall</surname> <given-names>HI</given-names></name>. <article-title>Using Molecular HIV Surveillance Data to Understand Transmission Between Subpopulations in the United States</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>70</volume>(<issue>4</issue>):<fpage>444</fpage>–<lpage>51</lpage>. Epub 2015/08/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/QAI.0000000000000809" xlink:type="simple">10.1097/QAI.0000000000000809</ext-link></comment> <object-id pub-id-type="pmid">26302431</object-id>; PubMed Central PMCID: PMC4878401.</mixed-citation></ref>
<ref id="pone.0182376.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hakre</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scoville</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Pacha</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Peel</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Michael</surname> <given-names>NL</given-names></name>, <etal>et al</etal>. <article-title>Brief Report: Sexual Risk Behaviors of HIV Seroconverters in the US Army, 2012–2014.</article-title> <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>70</volume>(<issue>4</issue>):<fpage>456</fpage>–<lpage>61</lpage>. Epub 2015/08/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/QAI.0000000000000778" xlink:type="simple">10.1097/QAI.0000000000000778</ext-link></comment> <object-id pub-id-type="pmid">26247893</object-id>; PubMed Central PMCID: PMC4627169.</mixed-citation></ref>
<ref id="pone.0182376.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pacha</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Hakre</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Myles</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Sanders-Buell</surname> <given-names>EE</given-names></name>, <name name-style="western"><surname>Scoville</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Kijak</surname> <given-names>GH</given-names></name>, <etal>et al</etal>. <article-title>Centralized HIV Program Oversight: An Investigation of a Case Series of New HIV Infections among US Army Soldiers, 2012 to 2013</article-title>. <source>Medicine (Baltimore)</source>. <year>2015</year>;<volume>94</volume>(<issue>46</issue>):<fpage>e2093</fpage>. Epub 2015/11/19. 10.1097/MD.000000000000209300005792-201511170-00027 [pii]. PubMed Central PMCID: PMC4652831. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MD.0000000000002093" xlink:type="simple">10.1097/MD.0000000000002093</ext-link></comment> <object-id pub-id-type="pmid">26579822</object-id></mixed-citation></ref>
<ref id="pone.0182376.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hakre</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Paris</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Brian</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Malia</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sanders-Buell</surname> <given-names>EE</given-names></name>, <name name-style="western"><surname>Tovanabutra</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Enhanced U.S. Army HIV diagnostic algorithm used to diagnose acute HIV infection in a deployed soldier</article-title>. <source>Mil Med</source>. <year>2012</year>;<volume>177</volume>(<issue>5</issue>):<fpage>609</fpage>–<lpage>13</lpage>. Epub 2012/06/01. <object-id pub-id-type="pmid">22645891</object-id>.</mixed-citation></ref>
<ref id="pone.0182376.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rubertone</surname> <given-names>MV</given-names></name>, <name name-style="western"><surname>Brundage</surname> <given-names>JF</given-names></name>. <article-title>The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance</article-title>. <source>Am J Public Health</source>. <year>2002</year>;<volume>92</volume>(<issue>12</issue>):<fpage>1900</fpage>–<lpage>4</lpage>. Epub 2002/11/28. <object-id pub-id-type="pmid">12453804</object-id>; PubMed Central PMCID: PMC1447349.</mixed-citation></ref>
<ref id="pone.0182376.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kearse</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Moir</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Stones-Havas</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sturrock</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>(<issue>12</issue>):<fpage>1647</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/bts199" xlink:type="simple">10.1093/bioinformatics/bts199</ext-link></comment> <object-id pub-id-type="pmid">22543367</object-id>; PubMed Central PMCID: PMCPMC3371832.</mixed-citation></ref>
<ref id="pone.0182376.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tamura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Stecher</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Peterson</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Filipski</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>S</given-names></name>. <article-title>MEGA6: Molecular Evolutionary Genetics Analysis version 6.0</article-title>. <source>Mol Biol Evol</source>. <year>2013</year>;<volume>30</volume>(<issue>12</issue>):<fpage>2725</fpage>–<lpage>9</lpage>. Epub 2013/10/18. 10.1093/molbev/mst197mst197 [pii]. PubMed Central PMCID: PMC3840312. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/molbev/mst197" xlink:type="simple">10.1093/molbev/mst197</ext-link></comment> <object-id pub-id-type="pmid">24132122</object-id></mixed-citation></ref>
<ref id="pone.0182376.ref010"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Information NCfB. Genotyping. 2017.</mixed-citation></ref>
<ref id="pone.0182376.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Schultz</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Calef</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kuiken</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Leitner</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Korber</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1</article-title>. <source>Nucleic Acids Res</source>. <year>2006</year>;<volume>34</volume>(Web Server issue):<fpage>W463</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkl255" xlink:type="simple">10.1093/nar/gkl255</ext-link></comment> <object-id pub-id-type="pmid">16845050</object-id>; PubMed Central PMCID: PMCPMC1538796.</mixed-citation></ref>
<ref id="pone.0182376.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oster</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Switzer</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Hernandez</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Saduvala</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Wertheim</surname> <given-names>JO</given-names></name>, <name name-style="western"><surname>Nwangwu-Ike</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Increasing HIV-1 subtype diversity in seven states, United States, 2006–2013</article-title>. <source>Ann Epidemiol</source>. <year>2017</year>;<volume>27</volume>(<issue>4</issue>):<fpage>244</fpage>–<lpage>51</lpage> e1. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.annepidem.2017.02.002" xlink:type="simple">10.1016/j.annepidem.2017.02.002</ext-link></comment> <object-id pub-id-type="pmid">28318764</object-id>.</mixed-citation></ref>
<ref id="pone.0182376.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reif</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pence</surname> <given-names>BW</given-names></name>, <name name-style="western"><surname>Hall</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Whetten</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>E</given-names></name>. <article-title>HIV Diagnoses, Prevalence and Outcomes in Nine Southern States</article-title>. <source>J Community Health</source>. <year>2015</year>;<volume>40</volume>(<issue>4</issue>):<fpage>642</fpage>–<lpage>51</lpage>. Epub 2014/12/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10900-014-9979-7" xlink:type="simple">10.1007/s10900-014-9979-7</ext-link></comment> <object-id pub-id-type="pmid">25524210</object-id>; PubMed Central PMCID: PMC4490182.</mixed-citation></ref>
<ref id="pone.0182376.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bradley</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hall</surname> <given-names>HI</given-names></name>, <name name-style="western"><surname>Wolitski</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Van Handel</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Stone</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>LaFlam</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2014</year>;<volume>63</volume>(<issue>47</issue>):<fpage>1113</fpage>–<lpage>7</lpage>. Epub 2014/11/27. mm6347a5 [pii]. <object-id pub-id-type="pmid">25426654</object-id>.</mixed-citation></ref>
<ref id="pone.0182376.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buot</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Docena</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Ratemo</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Bittner</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Burlew</surname> <given-names>JT</given-names></name>, <name name-style="western"><surname>Nuritdinov</surname> <given-names>AR</given-names></name>, <etal>et al</etal>. <article-title>Beyond race and place: distal sociological determinants of HIV disparities</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>e91711</fpage>. Epub 2014/04/20. 10.1371/journal.pone.0091711 PONE-D-13-37521 [pii]. PubMed Central PMCID: PMC3990614. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0091711" xlink:type="simple">10.1371/journal.pone.0091711</ext-link></comment> <object-id pub-id-type="pmid">24743728</object-id></mixed-citation></ref>
<ref id="pone.0182376.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forsyth</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Valdiserri</surname> <given-names>RO</given-names></name>. <article-title>A State-Level Analysis of Social and Structural Factors and HIV Outcomes Among Men Who Have Sex With Men in the United States</article-title>. <source>AIDS Educ Prev</source>. <year>2015</year>;<volume>27</volume>(<issue>6</issue>):<fpage>493</fpage>–<lpage>504</lpage>. Epub 2015/11/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1521/aeap.2015.27.6.493" xlink:type="simple">10.1521/aeap.2015.27.6.493</ext-link></comment> <object-id pub-id-type="pmid">26595263</object-id>.</mixed-citation></ref>
<ref id="pone.0182376.ref017"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Reif S, Whetten K, Wilson L, Gong W. HIV/AIDS epidemic in the South reaches crisis proportions in the last decade 2011 [cited 2016 August 18, 2016]. Available from: <ext-link ext-link-type="uri" xlink:href="https://southernaidsstrategy.org/research/" xlink:type="simple">https://southernaidsstrategy.org/research/</ext-link>.</mixed-citation></ref>
<ref id="pone.0182376.ref018"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Centers for Disease Control and Prevention. HIV Surveillance Report, 2012. 2014 Published November 2014. Report No.</mixed-citation></ref>
<ref id="pone.0182376.ref019"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. In: Services DoHaH, editor. 2016.</mixed-citation></ref>
<ref id="pone.0182376.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moore</surname> <given-names>RD</given-names></name>. <article-title>Epidemiology of HIV infection in the United States: implications for linkage to care</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume> <issue>Suppl 2</issue>:<fpage>S208</fpage>–<lpage>13</lpage>. Epub 2011/03/05. 10.1093/cid/ciq044 ciq044 [pii]. PubMed Central PMCID: PMC3106255. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciq044" xlink:type="simple">10.1093/cid/ciq044</ext-link></comment> <object-id pub-id-type="pmid">21342909</object-id></mixed-citation></ref>
<ref id="pone.0182376.ref021"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Department of the Army. Identification, surveillance, and administration of personnel infected with human immunodeficiency virus (HIV). AR 600–110 Army Regulation 600–110. 22 April 2014.</mixed-citation></ref>
<ref id="pone.0182376.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Branson</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Handsfield</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Lampe</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Janssen</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Taylor</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Lyss</surname> <given-names>SB</given-names></name>, <etal>et al</etal>. <article-title>Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings</article-title>. <source>MMWR Recomm Rep</source>. <year>2006</year>;<volume>55</volume>(<issue>RR-14</issue>):<fpage>1</fpage>–<lpage>17</lpage>; quiz CE1-4. Epub 2006/09/22. rr5514a1 [pii]. <object-id pub-id-type="pmid">16988643</object-id>.</mixed-citation></ref>
<ref id="pone.0182376.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hutchinson</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Farnham</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Sansom</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Yaylali</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mermin</surname> <given-names>JH</given-names></name>. <article-title>Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2016</year>;<volume>71</volume>(<issue>3</issue>):<fpage>323</fpage>–<lpage>30</lpage>. Epub 2015/09/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/QAI.0000000000000838" xlink:type="simple">10.1097/QAI.0000000000000838</ext-link></comment> <object-id pub-id-type="pmid">26361172</object-id>; PubMed Central PMCID: PMC4770372.</mixed-citation></ref>
<ref id="pone.0182376.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lucas</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Armbruster</surname> <given-names>B</given-names></name>. <article-title>The cost-effectiveness of expanded HIV screening in the United States</article-title>. <source>AIDS</source>. <year>2013</year>;<volume>27</volume>(<issue>5</issue>):<fpage>795</fpage>–<lpage>801</lpage>. Epub 2012/11/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/QAD.0b013e32835c54f9" xlink:type="simple">10.1097/QAD.0b013e32835c54f9</ext-link></comment> <object-id pub-id-type="pmid">23169333</object-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>